Product Overview
CJC-1295 (no DAC) and Ipamorelin is a research peptide blend combining two mechanistically distinct secretagogues that act synergistically on the growth hormone axis. CJC-1295 (Mod GRF 1–29) targets GHRH receptors, stimulating cAMP/PKA-mediated GH synthesis, while Ipamorelin binds the ghrelin receptor (GHS-R1a), activating Gq/11-linked calcium signaling pathways. Together, they serve as a model for studying peptide-induced GH pulsatility, receptor cross-talk, and hypothalamic–pituitary regulation in controlled experimental systems.
This product is a laboratory-formulated peptide blend consisting of CJC-1295 (No DAC; Modified GRF (1–29)) and Ipamorelin. The blend is supplied exclusively for research use to support mechanistic investigation of growth hormone axis signaling through coordinated activation of GHRHR and GHSR-1a in preclinical experimental systems. CJC-1295 (No DAC) is a synthetic GHRH analog derived from the N-terminal 29–amino-acid sequence of endogenous GHRH, engineered to increase resistance to proteolytic degradation while retaining high affinity for the GHRH receptor. Ipamorelin is a synthetic pentapeptide and a highly selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR-1a), used in laboratory studies to evaluate receptor-specific signaling with minimal off-target pituitary hormone activation.
Storage & Handling
Molecular Information
Quality Assurance
Every batch undergoes comprehensive third-party testing
HPLC Analysis
High-Performance Liquid Chromatography confirms peptide purity and identity
Mass Spectrometry
Molecular weight verification through advanced mass spec analysis
Endotoxin Testing
LAL assay confirms endotoxin levels meet strict specifications